OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 298.45 Million CAD | -48.28% |
| 2022 | 577.1 Million CAD | 4.17% |
| 2021 | 554.01 Million CAD | 32.66% |
| 2020 | 417.62 Million CAD | -2.54% |
| 2019 | 428.52 Million CAD | 41.63% |
| 2018 | 302.56 Million CAD | 226.01% |
| 2017 | 92.8 Million CAD | 72.29% |
| 2016 | 53.86 Million CAD | 279.98% |
| 2015 | 14.17 Million CAD | 10030.36% |
| 2014 | 139.93 Thousand CAD | -58.45% |
| 2013 | 336.76 Thousand CAD | -32.84% |
| 2012 | 501.44 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 299.01 Million CAD | 0.19% |
| 2024 Q3 | 354.74 Million CAD | 6.92% |
| 2024 Q2 | 331.77 Million CAD | 10.96% |
| 2023 Q3 | 348.51 Million CAD | -36.83% |
| 2023 Q1 | 573.22 Million CAD | -0.67% |
| 2023 Q2 | 551.73 Million CAD | -3.75% |
| 2023 FY | 298.45 Million CAD | -48.28% |
| 2023 Q4 | 298.45 Million CAD | -14.36% |
| 2022 Q1 | 545.36 Million CAD | -1.56% |
| 2022 Q2 | 585.1 Million CAD | 7.29% |
| 2022 Q3 | 583.56 Million CAD | -0.26% |
| 2022 FY | 577.1 Million CAD | 4.17% |
| 2022 Q4 | 577.1 Million CAD | -1.11% |
| 2021 Q2 | 392.76 Million CAD | -17.03% |
| 2021 Q3 | 576.71 Million CAD | 46.83% |
| 2021 Q4 | 554.01 Million CAD | -3.94% |
| 2021 FY | 554.01 Million CAD | 32.66% |
| 2021 Q1 | 473.37 Million CAD | 13.35% |
| 2020 Q3 | 433.67 Million CAD | -13.66% |
| 2020 Q2 | 502.27 Million CAD | 6.98% |
| 2020 Q1 | 469.48 Million CAD | 9.56% |
| 2020 Q4 | 417.62 Million CAD | -3.7% |
| 2020 FY | 417.62 Million CAD | -2.54% |
| 2019 Q4 | 428.52 Million CAD | 0.13% |
| 2019 FY | 428.52 Million CAD | 41.63% |
| 2019 Q3 | 427.98 Million CAD | 13.78% |
| 2019 Q2 | 376.15 Million CAD | 2.04% |
| 2019 Q1 | 368.62 Million CAD | 21.83% |
| 2018 Q4 | 302.56 Million CAD | 11.19% |
| 2018 FY | 302.56 Million CAD | 226.01% |
| 2018 Q1 | 96.6 Million CAD | 4.1% |
| 2018 Q2 | 268.77 Million CAD | 178.21% |
| 2018 Q3 | 272.12 Million CAD | 1.25% |
| 2017 Q1 | 57.07 Million CAD | 5.96% |
| 2017 Q2 | 91.21 Million CAD | 59.81% |
| 2017 FY | 92.8 Million CAD | 72.29% |
| 2017 Q3 | 89.37 Million CAD | -2.02% |
| 2017 Q4 | 92.8 Million CAD | 3.84% |
| 2016 FY | 53.86 Million CAD | 279.98% |
| 2016 Q3 | 21.56 Million CAD | 4.5% |
| 2016 Q2 | 20.63 Million CAD | 6.55% |
| 2016 Q1 | 19.36 Million CAD | 36.61% |
| 2016 Q4 | 53.86 Million CAD | 149.82% |
| 2015 Q1 | 10.24 Million CAD | 18.18% |
| 2015 FY | 14.17 Million CAD | 10030.36% |
| 2015 Q4 | 14.17 Million CAD | 17.11% |
| 2015 Q3 | 12.1 Million CAD | 0.49% |
| 2015 Q2 | 12.04 Million CAD | 17.63% |
| 2014 Q1 | 145.12 Thousand CAD | -54.74% |
| 2014 Q3 | 139.93 Thousand CAD | -3.39% |
| 2014 Q4 | 8.66 Million CAD | 6092.49% |
| 2014 Q2 | 144.84 Thousand CAD | -0.19% |
| 2014 FY | 139.93 Thousand CAD | -58.45% |
| 2013 Q2 | 337.05 Thousand CAD | -8.45% |
| 2013 Q1 | 368.17 Thousand CAD | -13.4% |
| 2013 FY | 336.76 Thousand CAD | -32.84% |
| 2013 Q4 | 320.65 Thousand CAD | -4.78% |
| 2013 Q3 | 336.76 Thousand CAD | -0.09% |
| 2012 Q4 | 425.14 Thousand CAD | -15.22% |
| 2012 Q3 | 501.44 Thousand CAD | -8.19% |
| 2012 Q2 | 546.19 Thousand CAD | 64.81% |
| 2012 Q1 | 331.4 Thousand CAD | 0.0% |
| 2012 FY | 501.44 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Theratechnologies Inc. | 77.76 Million USD | -283.771% |
| Harrow Health, Inc. | 311.75 Million USD | 4.266% |
| Dynavax Technologies Corporation | 997.09 Million USD | 70.068% |
| Biofrontera Inc. | 27.93 Million USD | -968.506% |
| Cronos Group Inc. | 1.13 Billion USD | 73.687% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1903.995% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 36.644% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -433.441% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1194.977% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -264.966% |
| Radius Health, Inc. | 1.71 Billion USD | 82.607% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -460.089% |
| DURECT Corporation | 45.18 Million USD | -560.459% |
| ProPhase Labs, Inc. | 91.92 Million USD | -224.665% |
| Safety Shot Inc | 12.7 Million USD | -2248.342% |
| Phibro Animal Health Corporation | 982.18 Million USD | 69.613% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1190.501% |
| Alvotech | 950.09 Million USD | 68.587% |
| Assertio Holdings, Inc. | 286.41 Million USD | -4.202% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 78.818% |
| Rockwell Medical, Inc. | 52.17 Million USD | -472.049% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -991.364% |
| Procaps Group S.A. | 460.18 Million USD | 35.145% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 59.02% |
| SCYNEXIS, Inc. | 128.41 Million USD | -132.42% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -152.725% |
| Viatris Inc. | 47.68 Billion USD | 99.374% |
| OptiNose, Inc. | 107.72 Million USD | -177.042% |
| SIGA Technologies, Inc. | 254.83 Million USD | -17.116% |
| Tilray Brands, Inc. | 4.33 Billion USD | 93.116% |
| PetIQ, Inc. | 868.22 Million USD | 65.625% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -991.364% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 90.821% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2404.2% |
| Alimera Sciences, Inc. | 153.52 Million USD | -94.403% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 73.895% |
| Silver Spike Investment Corp. | 88.57 Million USD | -236.947% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -4914.587% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 35.122% |
| Journey Medical Corporation | 76.84 Million USD | -288.365% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -783.113% |
| Alpha Teknova, Inc. | 128.58 Million USD | -132.104% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -855.27% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -9.044% |
| PainReform Ltd. | 9.93 Million USD | -2905.589% |
| Cosmos Health Inc. | 66.29 Million USD | -350.188% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -14.295% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -589.129% |
| Embecta Corp. | 1.21 Billion USD | 75.424% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -3436.946% |
| Talphera, Inc. | 20.39 Million USD | -1363.373% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 81.043% |
| Incannex Healthcare Limited | 17.04 Million USD | -1650.777% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2152.909% |
| Shineco, Inc. | 84.17 Million USD | -254.546% |
| Procaps Group, S.A. | 460.18 Million USD | 35.145% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 67.0% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -419.793% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 81.924% |
| Alvotech | 950.09 Million USD | 68.587% |
| Hempacco Co., Inc. | 18.04 Million USD | -1554.124% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 26.518% |
| Bright Green Corporation | 17.4 Million USD | -1614.958% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -45.025% |
| Kamada Ltd. | 351.96 Million USD | 15.204% |
| Indivior PLC | 1.95 Billion USD | 84.704% |
| Evoke Pharma, Inc. | 7.06 Million USD | -4122.297% |
| Flora Growth Corp. | 23.62 Million USD | -1163.248% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -2152.909% |
| Evolus, Inc. | 188.99 Million USD | -57.914% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 76.679% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 80.273% |
| Akanda Corp. | 8.83 Million USD | -3276.19% |